World's Best Scientists 2026 revealed!
Jonathan W. Friedberg

Jonathan W. Friedberg

D-Index & Metrics

Medicine

D-Index
87
Citations
35154
World Ranking
13478
National Ranking
6854

Overview

Jonathan W. Friedberg is affiliated with the University of Rochester in the United States and has contributed extensively to the field of medicine, particularly in oncology and pathology. Their research primarily addresses lymphoma diagnosis and treatment, chronic lymphocytic leukemia, as well as lung cancer and central nervous system lymphoma. Other areas of focus include CAR-T cell therapy, viral-associated cancers, and cancer genomics and diagnostics.

Their work spans several specialized subfields, including pathology and forensic medicine, oncology, genetics, pulmonary and respiratory medicine, and neurology. The volume of publications reflects a concentrated expertise in these areas, with a significant focus on hematologic malignancies and related therapies.

Frequent coauthors include:

  • Brad S. Kahl
  • John P. Leonard
  • Christopher R. Flowers
  • Nancy L. Bartlett
  • Brian K. Link

Jonathan W. Friedberg has published extensively in respected scientific journals. The most frequent publication venues are:

  • Blood
  • Journal of Clinical Oncology
  • Hematological Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances

Selected recent papers that illustrate their research focus are:

  • "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee," 2022, Blood
  • "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma," 2022, New England Journal of Medicine
  • "Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma," 2020, Journal of Clinical Oncology
  • "Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma," 2024, New England Journal of Medicine
  • "Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001," 2020, Journal of Clinical Oncology

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

    Jonathan W. Friedberg;Jeff Sharman;John Sweetenham;Patrick B. Johnston

  • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon

  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

    James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Jonathan W. Friedberg

  • Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors

    Andrea K. Ng;M. V. Patricia Bernardo;Edie Weller;Kendall Backstrand

  • Long-Term Survival and Competing Causes of Death in Patients With Early-Stage Hodgkin’s Disease Treated at Age 50 or Younger

    Andrea K. Ng;M. Patricia Bernardo;Edie Weller;Kendall H. Backstrand

  • Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

    Jonathan W. Friedberg;Philip Cohen;Ling Chen;K. Sue Robinson

  • Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study

    Gary H. Lyman;David C. Dale;Jonathan Friedberg;Jeffrey Crawford

  • Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

    Patrick J. Stiff;Joseph M. Unger;James R. Cook;Louis S. Constine

  • Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

    Jonathan W. Friedberg;Michael D. Taylor;James R. Cerhan;Christopher R. Flowers

  • Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

    Lindsay M. Morton;Susan L. Slager;James R. Cerhan;Sophia S. Wang

  • Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

    Leo I. Gordon;Fangxin Hong;Richard I. Fisher;Nancy L. Bartlett

  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

    Nancy L. Bartlett;Wyndham H. Wilson;Sin Ho Jung;Eric D. Hsi

  • Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

    Anas Younes;Catherine Thieblemont;Franck Morschhauser;Ian Flinn

  • US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

    Oliver W. Press;Oliver W. Press;Hongli Li;Heiko Schöder;David J. Straus

  • Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516—The Southwest Oncology Group

    Steven H. Bernstein;Joseph M. Unger;Michael LeBlanc;Jonathan Friedberg

  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

    NL Bartlett;D Niedzwiecki;JL Johnson;JW Friedberg

Frequent Co-Authors

Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
John P. Leonard
John P. Leonard Cornell University
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Richard I. Fisher
Richard I. Fisher Fox Chase Cancer Center
Christopher R. Flowers
Christopher R. Flowers The University of Texas MD Anderson Cancer Center
Bruce D. Cheson
Bruce D. Cheson Georgetown University
Louis S. Constine
Louis S. Constine University of Rochester Medical Center
Lisa M. Rimsza
Lisa M. Rimsza Mayo Clinic
Leo I. Gordon
Leo I. Gordon Northwestern University
Oliver W. Press
Oliver W. Press University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA opens various career pathways and related online degrees for aspiring healthcare professionals. If you are interested in patient care but want a flexible application process, you might explore nursing programs without TEAS requirements. These programs remove common testing barriers and make it easier for students to begin nursing studies.

For those seeking leadership roles in healthcare, an accelerated healthcare administration degree can prepare you for management opportunities quickly and conveniently online. Similarly, registered nurses aiming to advance can benefit from seamless pathways such as an ASN to NP (Associate of Science in Nursing to Nurse Practitioner) bridge program. These options enable you to grow your expertise and scope of practice efficiently.

In addition, there is high demand for professionals with an online bachelor's degree in nutrition, supporting patients' health through diet and wellness. Choosing a related degree or career pathway can lead to fulfilling roles beyond traditional medicine and create more options within the growing healthcare sector.

Best Scientists Citing Jonathan W. Friedberg

Trending Scientists